^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | bosutinib (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) + Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
Excerpt:
Relapsed or refractory B-cell ALL or CML in lymphoid blast phase; Philadelphia chromosome must be present at screening (as determined by cytogenetic analysis, fluorescence in situ hybridization [FISH], or polymerase chain reaction [PCR] [i.e., BCR-ABL positive])
Trial ID:
Source:
Title:
Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia
Published date:
05/15/2021
Excerpt:
...bosutinib in combination with inotuzumab ozogamicin. Eighteen patients were enrolled (Ph‐positive ALL...A complete response (CR) / CR with incomplete count recovery (CRi) was achieved in 15/18 (83%) patients; 11/18 (61%) patients achieved negative measurable residual disease by flow cytometry. Complete molecular response was noted in 10/18 (56%) patients....
DOI:
https://doi.org/10.1002/ajh.26238
Source:
Title:
INOTUZUMAB OZOGAMICIN WITH BOSUTINIB IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE (CML-LBP)
Published date:
05/14/2020
Excerpt:
Eighty-three percent pts (15/18) achieved CR/CRi. Median time to response was 1 mo (range 0.8-2.1). After a median follow-up of 32 mo, the median overall survival was 15.4 mo and median event-free survival censored at allogeneic stem-cell transplantation (allo-SCT) was 6.1 mo (Fig. 1)....INO + bosutinib is well tolerated and shows promising activity in R/R Ph+ ALL and CML LBP.
Trial ID: